Clinical Trial: DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07024693) titled 'DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy' on May 20.

Brief Summary: The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.

Study Start Date: July, 2025

Study Type: INTERVENTIONAL

Condition: Fuchs Endothelial Corneal Dystrophy Fuchs

Intervention: DRUG: DT-168

Active

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Design Therapeutics, Inc.

Published by HT Digital Content Services with permission from Health Daily Digest....